|
1
|
Tilly H, Vitolo U, Walewski J, da Silva
MG, Shpilberg O, André M, Pfreundschuh M and Dreyling M: ESMO
Guidelines Working Group: Diffuse large B-cell lymphoma (DLBCL):
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 23(Suppl 7): vii78–vii82. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molina A: A decade of rituximab: Improving
survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med.
59:237–250. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jazirehi AR and Bonavida B: Cellular and
molecular signal transduction pathways modulated by rituximab
(Rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implications in
chemosensitization and therapeutic intervention. Oncogene.
24:2121–2143. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Plosker GL and Figgitt DP: Rituximab: A
review of its use in non-Hodgkin's lymphoma and chronic lymphocytic
leukaemia. Drugs. 63:803–843. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhuang Y, Xu W, Shen Y and Li J: Fcγ
receptor polymorphisms and clinical efficacy of rituximab in
non-Hodgkin' lymphoma and chronic lymphocytic leukemia. Clin
Lymphoma Myeloma Leuk. 10:347–352. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ravetch JV and Bolland S: IgG Fc
receptors. Annu Rev Immunol. 19:275–290. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Parren PW, Warmerdam PA, Boeije LC, Arts
J, Westerdaal NA, Vlug A, Capel PJ, Aarden LA and van de Winkel JG:
On the interaction of IgG subclasses with the low affinity Fc gamma
RIIa (CD32) on human monocytes, neutrophils, and platelets.
Analysis of a functional polymorphism to human IgG2. J Clin Invest.
90:1537–1546. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koene HR, Kleijer M, Algra J, Roos D, von
dem Borne AE and de Haas M: Fc gammaRIIIa-158V/F polymorphism
influences the binding of IgG by natural killer cell Fc gammaRIIIa,
independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood.
90:1109–1114. 1997.PubMed/NCBI
|
|
9
|
de Haas M, Koene HR, Kleijer M, de Vries
E, Simsek S, van Tol MJ, Roos D and von dem Borne AE: A triallelic
Fc gamma receptor type IIIA polymorphism influences the binding of
human IgG by NK cell Fc gamma RIIIa. J Immunol. 156:2948–2955.
1996.PubMed/NCBI
|
|
10
|
Hatjiharissi E, Hansen M, Santos DD, Xu L,
Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ,
et al: Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and
implications for their use in predicting clinical responses to
CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma.
7:286–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Warmerdam PA, van de Winkel JG, Vlug A,
Westerdaal NA and Capel PJ: A single amino acid in the second
Ig-like domain of the human Fc gamma receptor II is critical for
human IgG2 binding. J Immunol. 147:1338–1343. 1991.PubMed/NCBI
|
|
12
|
Ahlgrimm M, Pfreundschuh M, Kreuz M,
Regitz E, Preuss KD and Bittenbring J: The impact of Fc-γ receptor
polymorphisms in elderly patients with diffuse large B-cell
lymphoma treated with CHOP with or without rituximab. Blood.
118:4657–4662. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cartron G, Dacheux L, Salles G,
Solal-Celigny P, Bordos P, Colombat P and Watier H: Therapeutic
activity of humanized anti-CD20 monoclonal antibody and
polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood.
99:754–758. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Treon SP, Hansen M, Branagan AR, Verselis
S, Emmanouilides C, Kimbey E, Frankel SR, Touroutoglou N, Turnbull
B, Anderson KC, et al: Polymorphisms in FcgammaRIIIa (CD16)
receptor expression are associated with clinical response to
rituximab in Waldenström's macroglobulinaemia. J Clin Oncol.
23:474–481. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weng WK and Levy R: Two immunoglobulin G
fragment C receptor polymorphisms independently predict response to
rituximab in patients with follicular lymphoma. J Clin Oncol.
21:3940–3947. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim DW, Jung HD, Kim JG, Lee JJ, Yang DH,
Park YH, Do YR, Shin HJ, Kim MK, Hyun MS and Sohn SK: FCGR3A gene
polymorphisms may correlate with response to frontline R-CHOP
therapy for diffuse large B-cell lymphoma. Blood. 108:2720–2725.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Institute of Oncology Ljubljana
[Internet]. Ljubljana, Slovenia: Smernice za obravnavo bolnikov z
malignimi limfomi. https://www.onko-i.si/uploads/media/Doktrina_limfomi_2015.docAccessed.
Feb 11–2015
|
|
18
|
Cheson BD, Horning SJ, Coiffier B, Shipp
MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A,
Hagenbeek A, et al: Report of an international workshop to
standardize response criteria for non-Hodgkin's lymphomas. NCI
Sponsored International Working Group. J Clin Oncol.
17:12441999.PubMed/NCBI
|
|
19
|
Rohtagi S, Gohil S, Kuniholm MH, Schultz
H, Dufaud C, Armour KL, Badri S, Mailliard RB and Pirofski LA: Fc
gamma receptor 3A polymorphism and risk for HIV-associated
cryptococcal disease. MBio. 4:e00573–e00613. 2013.PubMed/NCBI
|
|
20
|
Mitrovic Z, Aurer I, Radman I, Ajdukoviç
R, Sertiç J and Labar B: FCgammaRIIIA and FCgammaRIIa polymorphisms
are not associated with response to rituximab and CHOP in patients
with diffuse large B-cell lymphoma. Haematologica. 92:998–999.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fabisiewicz A, Paszkiewicz-Kozik E,
Osowiecki M, Walewski J and Siedlecki JA: FcγRIIA and FcγRIIIA
polymorphisms do not influence survival and response to rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone
immunochemotherapy in patients with diffuse large B-cell lymphoma.
Leuk Lymphoma. 52:1604–1606. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Váróczy L, Zilahi E, Gyetvai A, Kajtár B,
Gergely L, Sipka S and Illés A: Fc-gamma-receptor IIIa polymorphism
and gene expression profile do not predict the prognosis in diffuse
large B-cell lymphoma treated with R-CHOP protocol. Pathol Oncol
Res. 18:43–48. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Carlotti E, Palumbo GA, Oldani E, Tibullo
D, Salmoiraghi S, Rossi A, Golay J, Pulsoni A, Foà R and Rambaldi
A: FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict
clinical outcome of follicular non-Hodgkin's lymphoma patients
treated with sequential CHOP and rituximab. Haematologica.
92:1127–1130. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hurvitz SA, Betting DJ, Stern HM, Quinaux
E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, et
al: Analysis of Fcγ receptor IIIa and IIa polymorphisms: Lack of
correlation with outcome in trastuzumab-treated breast cancer
patients. Clin Cancer Res. 18:3478–3486. 2012. View Article : Google Scholar : PubMed/NCBI
|
